Imperial College London
Portrait Picture

ProfessorStephenDurham

Faculty of Medicine, National Heart & Lung Institute

Professor of Allergy and Respiratory
 
 
 
//

Contact

 

+44 (0)20 7351 8024s.durham

 
 
//

Location

 

Fulham RoadRoyal Brompton Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Pfaar:2021:10.1111/all.14957,
author = {Pfaar, O and Bergmann, K-C and Bonini, S and Compalati, E and Domis, N and de, Blay F and de, Kam P-J and Devillier, P and Durham, SR and Ellis, AK and Gherasim, A and Haya, L and Hohlfeld, JM and Horak, F and Iinuma, T and Jacobs, RL and Jacobi, HH and Jutel, M and Kaul, S and Kelly, S and Klimek, L and Larché, M and Lemell, P and Mahler, V and Nolte, H and Okamoto, Y and Patel, P and Rabin, RL and Rather, C and Sager, A and Salapatek, AM and Sigsgaard, T and Togias, A and Willers, C and Yang, WH and Zieglmayer, R and Zuberbier, T and Zieglmayer, P},
doi = {10.1111/all.14957},
journal = {Allergy},
pages = {3589--3612},
title = {Technical standards in allergen exposure chambers worldwide - an EAACI Task Force Report.},
url = {http://dx.doi.org/10.1111/all.14957},
volume = {76},
year = {2021}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Allergen exposure chambers (AECs) can be used for controlled exposure to allergenic and non-allergenic airborne particles in an enclosed environment, in order to (i) characterize the pathological features of respiratory diseases and (ii) contribute to and accelerate the clinical development of pharmacological treatments and allergen immunotherapy for allergic disease of the respiratory tract (such as allergic rhinitis, allergic rhinoconjunctivitis, and allergic asthma). In the guidelines of the European Medicines Agency for the clinical development of products for allergen immunotherapy (AIT), the role of AECs in determining primary endpoints in dose-finding Phase II trials is emphasized. Although methodologically insulated from the variability of natural pollen exposure, chamber models remain confined to supporting secondary, rather than primary, endpoints in Phase III registration trials. The need for further validation in comparison with field exposure is clearly mandated. On this basis, the European Academy of Allergy and Clinical Immunology (EAACI) initiated a Task Force in 2015 charged to gain a better understanding of how AECs can generate knowledge about respiratory allergies and can contribute to the clinical development of treatments. Researchers working with AECs worldwide were asked to provide technical information in eight sections: (i) dimensions and structure of the AEC, (ii) AEC staff, (iii) airflow, air processing, and operating conditions, (iv) particle dispersal, (v) pollen/particle counting, (vi) safety and non-contamination measures, (vii) procedures for symptom assessments, (viii) tested allergens/substances and validation procedures. On this basis, a minimal set of technical requirements for AECs applied to the field of allergology is proposed.
AU  - Pfaar,O
AU  - Bergmann,K-C
AU  - Bonini,S
AU  - Compalati,E
AU  - Domis,N
AU  - de,Blay F
AU  - de,Kam P-J
AU  - Devillier,P
AU  - Durham,SR
AU  - Ellis,AK
AU  - Gherasim,A
AU  - Haya,L
AU  - Hohlfeld,JM
AU  - Horak,F
AU  - Iinuma,T
AU  - Jacobs,RL
AU  - Jacobi,HH
AU  - Jutel,M
AU  - Kaul,S
AU  - Kelly,S
AU  - Klimek,L
AU  - Larché,M
AU  - Lemell,P
AU  - Mahler,V
AU  - Nolte,H
AU  - Okamoto,Y
AU  - Patel,P
AU  - Rabin,RL
AU  - Rather,C
AU  - Sager,A
AU  - Salapatek,AM
AU  - Sigsgaard,T
AU  - Togias,A
AU  - Willers,C
AU  - Yang,WH
AU  - Zieglmayer,R
AU  - Zuberbier,T
AU  - Zieglmayer,P
DO  - 10.1111/all.14957
EP  - 3612
PY  - 2021///
SP  - 3589
TI  - Technical standards in allergen exposure chambers worldwide - an EAACI Task Force Report.
T2  - Allergy
UR  - http://dx.doi.org/10.1111/all.14957
UR  - https://www.ncbi.nlm.nih.gov/pubmed/34028057
VL  - 76
ER  -
Download